Patient characteristics and distribution of serum samples based on premortem classification of treatment episodes
| . | Proven IA . | Probable IA . | Probable IFI . | Possible IFI . | No IA . | Total . |
|---|---|---|---|---|---|---|
| Patients, no. | 7 | 29 | 2 | 83 | 132 | 191 |
| Age, y | ||||||
| Mean | 45.7 | 50 | 55 | 44.8 | 41.4 | 44.4 |
| Median | 46 | 52 | 55 | 45 | 40 | 45 |
| Range | 26-69 | 27-79 | NA | 17-82 | 16-76 | 16-82 |
| Sex, M/F | 5/2 | 17/12 | 1/1 | 57/26 | 90/42 | 131/60 |
| Episodes, no. (%) | 7 (1.9) | 30 (8.3) | 2 (0.5) | 97 (26.8) | 226 (62.4) | 362 (100) |
| AML | 1 | 9 | 1 | 43 | 69 | 123 (33.9) |
| ALL | 1 | 4 | 7 | 30 | 42 (11.6) | |
| Total acute leukemia | 165 (45.5) | |||||
| Lymphoblastic lymphoma | — | 7 | 5 | 10 | 22 (6) | |
| Myelodysplasia | 1 | 2 | 1 | 14 | 34 | 52 (14.3) |
| Allogeneic SCT | — | 3 | 18 | 45 | 66 (18.2) | |
| Follow-up | 4 | 5 | 8 | 29 | 46 (12.7) | |
| CML | — | — | 2 | 9 | 11 (3) | |
| Neutropenic episodes, no. (%) | 2 | 26 | 2 | 87 | 193 | 310 (85.6) |
| Duration, d | ||||||
| Mean | 35 | 25.3 | NA | 20.5 | 20 | 20.7 |
| Median | 35 | 19 | NA | 23.9 | 19 | 19 |
| Range | 35-69 | 6-64 | 10-22 | 3-75 | 2-57 | 2-75 |
| Episodes with corticosteroids, no. (%) | 5 (71.4) | 15 (50) | 1 (50) | 31 (31.9) | 63 (27.8) | 115 (31.7) |
| Episodes with bacteremia, no. (%) | 3 (42.8) | 12 (40) | 2 (100) | 55 (56.7) | 109 (48.2) | 181 (50) |
| Samples per episode, no. | 256 | 529 | 12 | 1119 | 2384 | 4300 |
| Mean | 36.5 | 17.6 | NA | 11.5 | 10.5 | 11.8 |
| Median | 33 | 14.5 | NA | 9.5 | 8.5 | 9 |
| Range | 26-65 | 4-62 | 4-8 | 2-66 | 3-56 | 2-66 |
| Pos episodes, no. (%) | 7 (100) | 20 (66.6) | 0 | 15 (15.5) | 2 (0.9) | 44 (12.1) |
| Pos samples, no. (%) | 116 (45.1) | 218 (41.2) | 0 | 157 (14) | 11 (0.5) | 502 (11.7) |
| Per pos episodes, no. | ||||||
| Mean | 19 | 10.9 | NA | 10.5 | 5.5 | 11.2 |
| Median | 13.5 | 7 | NA | 5.5 | 5.5 | 9.5 |
| Range | 2-50 | 2-54 | NA | 2-52 | 4-7 | 2-54 |
| Single sample with pos episodes, no. (%) | 0 | 2 | 0 | 3 | 7 | 12 (3.3) |
| Episodes with antifungals, no. (%) | 7 (100) | 30 (100) | 2 (100) | 84 (86.6) | 35 (15.4) | 158 (43.6) |
| . | Proven IA . | Probable IA . | Probable IFI . | Possible IFI . | No IA . | Total . |
|---|---|---|---|---|---|---|
| Patients, no. | 7 | 29 | 2 | 83 | 132 | 191 |
| Age, y | ||||||
| Mean | 45.7 | 50 | 55 | 44.8 | 41.4 | 44.4 |
| Median | 46 | 52 | 55 | 45 | 40 | 45 |
| Range | 26-69 | 27-79 | NA | 17-82 | 16-76 | 16-82 |
| Sex, M/F | 5/2 | 17/12 | 1/1 | 57/26 | 90/42 | 131/60 |
| Episodes, no. (%) | 7 (1.9) | 30 (8.3) | 2 (0.5) | 97 (26.8) | 226 (62.4) | 362 (100) |
| AML | 1 | 9 | 1 | 43 | 69 | 123 (33.9) |
| ALL | 1 | 4 | 7 | 30 | 42 (11.6) | |
| Total acute leukemia | 165 (45.5) | |||||
| Lymphoblastic lymphoma | — | 7 | 5 | 10 | 22 (6) | |
| Myelodysplasia | 1 | 2 | 1 | 14 | 34 | 52 (14.3) |
| Allogeneic SCT | — | 3 | 18 | 45 | 66 (18.2) | |
| Follow-up | 4 | 5 | 8 | 29 | 46 (12.7) | |
| CML | — | — | 2 | 9 | 11 (3) | |
| Neutropenic episodes, no. (%) | 2 | 26 | 2 | 87 | 193 | 310 (85.6) |
| Duration, d | ||||||
| Mean | 35 | 25.3 | NA | 20.5 | 20 | 20.7 |
| Median | 35 | 19 | NA | 23.9 | 19 | 19 |
| Range | 35-69 | 6-64 | 10-22 | 3-75 | 2-57 | 2-75 |
| Episodes with corticosteroids, no. (%) | 5 (71.4) | 15 (50) | 1 (50) | 31 (31.9) | 63 (27.8) | 115 (31.7) |
| Episodes with bacteremia, no. (%) | 3 (42.8) | 12 (40) | 2 (100) | 55 (56.7) | 109 (48.2) | 181 (50) |
| Samples per episode, no. | 256 | 529 | 12 | 1119 | 2384 | 4300 |
| Mean | 36.5 | 17.6 | NA | 11.5 | 10.5 | 11.8 |
| Median | 33 | 14.5 | NA | 9.5 | 8.5 | 9 |
| Range | 26-65 | 4-62 | 4-8 | 2-66 | 3-56 | 2-66 |
| Pos episodes, no. (%) | 7 (100) | 20 (66.6) | 0 | 15 (15.5) | 2 (0.9) | 44 (12.1) |
| Pos samples, no. (%) | 116 (45.1) | 218 (41.2) | 0 | 157 (14) | 11 (0.5) | 502 (11.7) |
| Per pos episodes, no. | ||||||
| Mean | 19 | 10.9 | NA | 10.5 | 5.5 | 11.2 |
| Median | 13.5 | 7 | NA | 5.5 | 5.5 | 9.5 |
| Range | 2-50 | 2-54 | NA | 2-52 | 4-7 | 2-54 |
| Single sample with pos episodes, no. (%) | 0 | 2 | 0 | 3 | 7 | 12 (3.3) |
| Episodes with antifungals, no. (%) | 7 (100) | 30 (100) | 2 (100) | 84 (86.6) | 35 (15.4) | 158 (43.6) |
IA indicates invasive aspergillosis; IFI, invasive fungal infection; NA, not applicable; M, male; F, female; ALL, acute lymphoblastic leukemia; SCT, stem cell transplantation; and pos, positive.